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ABSTRACT
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support 
and drug release to prevent early recoil or restenosis, and then degrades into nontoxic 
compounds to avoid late complications related with metallic drug-eluting stents (DESs). 
BRS has several putative advantages. However, recent randomized trials and registry studies 
raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the 
general guidance for the optimal practice with BRS has not been suggested due to limited 
long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the 
clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and 
lesion selection, scaffold implantation technique, and management.
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INTRODUCTION
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support 
and drug release to prevent early recoil or restenosis, and then degrades into nontoxic 
compounds to avoid late complications related with metallic drug-eluting stents (DESs). 
BRS has several putative advantages including early restoration of physiological processes, 
superior conformability, beneficial edge-vascular response and suppression of late-stent 
malapposition.1) In addition, 5-years follow-up of BRS showed late lumen enlargement and 
restoration of vasomotor response and suggested a possible plaque stabilizing effect.2-4) 
However, recent randomized trials and registry studies raised clinical concerns about the 
safety and efficacy of first generation BRS. They showed that higher rate of procedural related 
myocardial infarction (MI), and scaffold thrombosis compared with metallic DES.5)6) Thus, 
at March 2017, the US Food and Drug Administration (FDA) warned physicians that treating 
patients with first generation BRS.
BRS has been commercially available in Korea since January 2016, and as of August 2017, about 
2,800 BRSs were implanted. However, the general guidance for the optimal practice with BRS 
has not been suggested due to limited long-term clinical data in Korea. Therefore, at 4th August 
2017, 18 Korean heart centers combined efforts to address clinical issues raised by previous 
studies. We reviewed the clinical evidence of BRS implantation, and suggested the appropriate 
criteria for patient and lesion selection, scaffold implantation technique, and management. 
The scope of this document is limited to the Absorb Bioresorbable Vascular Scaffold (Absorb 
BRS; Abbott Vascular, Abbott Park, IL, USA), which is the only available BRS in Korea.
DEVICE DESCRIPTION
The Absorb BRS (Abbott Vascular) consists of a 157-μm-thick bioresorbable poly (L-lactide) 
scaffold with a 7-μm-thick bioresorbable poly (D,L-lactide) coating, which elutes everolimus 
(7). About 80% of the drug elutes in the first 30 days, and the remainder elutes over 120 days. 
Scaffold are fully bioresorbable, with complete bioresorption expected by approximately 
24 to 36 months. The initial reduction in molecular weight, the decrease in radial support 
occurs at approximately equal to 6 months, and finally the loss in mass starts at 12 months 
(Figure 1).8) To compared with metallic DESs, BRS has less acute gain, and smaller lumen 
area. In addition, it has a limited expansion capability. Experimental in-vitro study indicated 
the fracture threshold was +1.0 mm. Overexpansion beyond this threshold can lead to strut 
disconnections and focal loss of mechanical support.9)
CURRENT EVIDENCE
Early pilot trials
The ABSORB cohort A and B experiences provided objective characterization of BRS 
resorption and coronary healing process in humans.10)11) Serial intravascular imaging studies 
showed that strut resorption and vascular healing after BRS implantation were associated with 
late lumen enlargement.2) The formation of a neointima layer after BRS resorption suggested 
to seal or “cap” the necrotic core plaque, and to prevent plaque rupture in the future.3) In 
addition, the restoration of vasomotor response to stimuli was demonstrated by 5 years.4) Early 
promising results called for clinical comparison studies with standard metallic DES.
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Randomized trials
ABSORB II is the first randomized controlled trial to compare Absorb BRS with everolimus-
eluting stent (EES) in 501 patients.1) The primary endpoint was angiographic vasomotor 
reactivity after nitrate injection and angiographic late luminal loss. At 1 year, first new or 
worsening angina was lower with BRS, although clinical outcomes were similar between 
groups. However, at 3-year follow-up, the vasomotor reactivity, angina status, and exercise 
capacity were not different. In addition, the late luminal loss was larger in the BRS group. 
The rate of a device-oriented composite endpoint (DOCE) was significantly higher in the BRS 
group, mainly driven by target vessel MI. Definite or probable device thrombosis was also 
significantly higher in the BRS group (Figure 2).5)
ABSORB III is the first large-scale, multicenter, randomized trial for US FDA regulatory 
approval.7) This study enrolled 2,008 patients with relatively simple coronary lesions. This 
study demonstrated that the BRS group was non-inferior to the EES group in the respective to 
target lesion failure (TLF) at 1-year. However, the 2-year results presented at American College 
of the Cardiology (ACC) 2017 that the rates of TLF were significantly higher in the BRS group 
due to the increased risk of target vessel MI in the BRS group. However, ABSORB China and 
ABSORB Japan at EuroPCR 2017 showed that BRS had comparable safety and efficacy to EESs 
at 3 years.
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Figure 1. Scaffold biodegradation. (A) Hydrolysis randomly cleaves amorphous tie chains, leading to a decrease in molecular weight without altering radial 
strength. (B) When enough tie chains are broken, the device begins losing radial strength. After 2–3 years, BRS was fully bioresorbed. 
BRS = bioresorbable vascular scaffold.
Recently, the Amsterdam Investigator-initiateD Absorb Strategy (AIDA) study reported early 
because of the higher incidence of device thrombosis in the BRS group.6) This study enrolled 
1,845 patients with more complex lesion subset than ABSORB III trial in the context of 
routine clinical practice: acute coronary syndrome (ACS) was 54% and small vessel disease 
was about 20%. In addition, postdilatation (74%) was still underused. Although target vessel 
failure (TVF) was not significantly different, device thrombosis, and subsequently target 
vessel myocadial infarction were significantly higher in the BRS group. Table 1 summarized 
currently available randomized trials.
Update meta-analysis of 2-year outcomes from 7 randomized trials showed that BRS had 
higher 2-year risk of the DOCE than EES.12) This difference was mainly derived from target 
vessel MI and ischemic-driven target lesion revascularization (TLR). In addition, device 
thrombosis was significantly higher in the BRS group. However, cardiac mortality was not 
different between groups (Figure 3).
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Figure 2. A case of acute scaffold thrombosis. (A) Baseline coronary angiography, (B) after Absorb 3.0×23 mm BRS implantation, (C) follow-up coronary 
angiography due to chest pain with ST elevation after 7 hours, (D) OCT showing acute scaffold thrombosis with underexpansion and malapposition, (E) final 
angiography after high-pressure balloon dilatation, and (F) final OCT image showing well-apposed scaffold. 
BRS = bioresorbable vascular scaffold; OCT = optical coherent tomography.
Table 1. Summary of randomized trials with the Absorb BRS
Clinical trial No. of patients  (BRS:DES) Primary endpoint Primary outcome
DOCE rate  
(BRS vs. DES)
Scaffold thrombosis rate 
(BRS vs. DES)
ABSORB II1) 501 (335:166) Vasomotor reactivity/angiographic 
lumen loss at 3 years
0.47 mm vs. 0.56 mm (p=0.49)/ 
0.37 mm vs. 0.25 mm (pnon-inferiority=0.78)
5% vs. 3% (p=0.35) 0.9% vs. 0% (p=0.55)
ABSORB III7) 2,008 (1,322:686) Target-lesion failure at 1 year 7.8% vs. 6.1% (p=0.16, pnon-inferiority=0.007) Same as primary outcome 1.5% vs. 0.7% (p=0.13)
ABSORB Japan42) 400 (266:134) Target-lesion failure at 1 year 4.2% vs. 3.8% (pnon-inferiority<0.0001) Same as primary outcome 1.5% vs. 1.5% (p>0.99)
ABSORB China43) 480 (241:239) In-segment lumen loss at 1 year 0.19 mm vs. 0.13 mm (p=0.01) 3.4% vs. 4.2% (p=0.62) 0.4% vs. 0% (p>0.99)
EVERBIO II64) 240 (80:160) Late lumen loss at 9 months 0.28±0.39 mm  
vs. 0.25±0.36 mm (p=0.30)
12% vs. 9% (p=0.6) 1.3% vs. 0%
TROFI II65) 191 (95:96) Healing score at 6 months 1.74 vs. 2.80 (pnon-inferiority<0.001) 1.1% vs. 0% 1.1% vs. 0%
AIDA6) 1,845 (924:921) Target-vessel failure at 2 years 11.7% vs. 10.7% (p=0.43) 10.3% vs. 8.9% (p=0.31) 3.5% vs. 0.9% (p<0.001)
AIDA = Amsterdam Investigator-initiated Absorb Strategy; BRS = bioresorbable vascular scaffold; DES = drug-eluting stent; DOCE = device-oriented composite 
endpoint; EVERBIO = Comparison of Everolimus- and Biolimus-Eluting Coronary Stents with Everolimus-Eluting Bioresorbable Vascular Scaffold; TROFI II 
= Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug-Eluting Metal Stent (Xience™) in Acute ST-Elevation 
Myocardial Infarction.
Registry studies
The Gauging coronary Healing with bioresorbable Scaffolding plaTforms in EUrope (GHOST-
EU) registry evaluated the performance of the Absorb BRS in a real-world practice from 10 
European heart centers.13) The incidence of TLF was 2.2% at 30 days and 4.4% at 6 months. 
However, definite or probable scaffold thrombosis was 1.5% at 30 days and 2.1% at 6 months. 
ABSORB expand registry reported that 12-month clinical outcomes in the first 512 patients.14) 
At one year, the ischemia-driven TVF was 4.9%. The cumulative rate of definite and probable 
scaffold thrombosis for this population was 0.8%. A Prospective, Randomized Trial of 
Bioresorbable Vascular Scaffold Versus Everolimus Eluting Stent in Patients Undergoing 
Coronary Stenting for Myocardial Infarction (ISAR-ABSORB MI) registry enrolled more 
complex population with diabetes (31.5%), ACS (39.0%), and bifurcation (13.1%).15) At 2 
years, the composite of death, MI, or TLR occurred in 21.6%. Definite scaffold thrombosis 
occurred in 3.8%. This study showed the higher event rates than expected, which raised 
concerns about the daily use of BRS. The Registro Absorb Italiano (RAI) registry enrolled 
1,505 patients (22.4% diabetes, 59.6% ACS) from 23 Italian heart centers16). All lesions 
were predilated and 96.8% lesions were post-dilated after BRS implantation. At 30 days, 
TLR occurred in 0.6% and definite or probable scaffold thrombosis occurred in 0.8%. This 
registry suggested that when accurate BRS implantation technique was used, an unrestricted 
BRS use would be safe and effective.17-21) In addition, BRS was evaluated in the complex 
patients and lesions subset including diabetes,22) ACS,23-25) MI,26-33) small vessel,34) and in-stent 
restenosis.35-37) However, the interpretation of such studies should be careful considering the 
biased nature of registry studies. Table 2 summarized currently available registry studies.
799https://e-kcj.org https://doi.org/10.4070/kcj.2017.0300
BRS Expert Consensus
B
2 
ye
ar
 e
ve
nt
 ra
te
 (%
)RR, 0.80; 95% CI, 0.57–1.12; p=0.19
2.1
3.0
5.8
3.2
RR, 1.68; 95% CI, 1.29–2.19; p<0.001
All-cause mortality TV-MI
Ischemic-driven TLR Definite device thrombosis
8
6
4
0
2
A
2 
ye
ar
 e
ve
nt
 ra
te
 (%
)
8
6
4
0
2
D
2 
ye
ar
 e
ve
nt
 ra
te
 (%
)RR, 1.40; 95% CI, 1.09–1.80; p=0.009
5.3
2.4 2.1
0.5
RR, 3.95; 95% CI, 1.96–5.72; p<0.0018
6
4
0
2
C
2 
ye
ar
 e
ve
nt
 ra
te
 (%
)
8
6
4
0
2
BRS EES
Figure 3. Meta-analysis from 7 randomized trials: 2 year outcomes. 
BRS = bioresorbable vascular scaffold; CI = confidence interval; EES = everolimus-eluting stent; RR = relative risk; TLR = target lesion revascularization; TV-MI = 
target vessel myocardial infarction.
RISK FACTORS FOR SCAFFOLD THROMBOSIS
Risk factors for scaffold thrombosis were multifactorial in the combination of the device, 
procedural, and patient factors. Mainz IntraCoronAry daTabase (MICAT) registry enrolled 
42 scaffold thrombosis. Multivariate analysis showed that ostial lesions and impaired left 
ventricular ejection fraction were independent predictors of scaffold thrombosis. In addition, 
early discontinuation of dual antiplatelet therapy (DAPT) was frequent in those patients. 
Most striking finding was that a BRS-specific implantation strategy reduced 12-months 
scaffold thrombosis rate from 3.3% to 1.0% (Figure 4).18)
Recent meta-analysis from ABSORB trials reported that diabetes and preprocedural reference 
vessel diameter (<2.25 mm vs. ≥2.25 mm) were independent predictors for definite or 
probable device thrombosis.12)
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Table 2. Summary of registry studies with the Absorb BRS
Trial/author Study design Population/lesion subset
No. of 
patients
Duration of 
follow-up
Composite 
endpoint (%)
MI  
(%)
TLR  
(%)
Definite/probable 
ST (%)
Absorb cohort A10) Multi-center, prospective Non-complex 30 5 years MACE: 3.4 3.4 3.4 0
Absorb cohort B11) Multi-center, prospective Non-complex 101 5 years MACE: 11 3.0 11 N/A
GHOST-EU13) Multi-center, retrospective All-comers 1,189 6 months TLF: 4.4 2.0 2.5 2.1
Absorb EXTEND14) Multi-center, prospective All-comers 512 1 year MACE: 4.3 2.9 1.8 0.8
ISAR-ABSORB MI15) Multi-center, prospective All-comers 419 2 years MACE: 21.6 3.9 16.0 3.8
Prospective RAI16) Multi-center, prospective All-comers 1505 30 days DOCE: 1.0 2.0 0.6 0.8
ASSURE17) Multi-center, prospective All-comers 183 12 months MACE: 5.0 1.7 2.8 0
MICAT18) Multi-center, retrospective All-comers 1305 485 days N/A N/A N/A 3.0
AMC single centre real world  
PCI registry19)
Single-center, prospective All-comers 135 6 months TVF: 8.5 3.0 6.3 3.0
Polish national registry20) Multi-center, retrospective All-comers 468 12 months MACE: 3.0 1.7 N/A 0.4
BVS Expand21) Single-center, prospective All-comers 249 18 months MACE: 6.8 5.2 4.0 1.9
Muramatsu et al.22) Pooled analysis of ABSORB, SPIRIT trials DM 102 1 year DOCE: 3.9 2.9 2.0 1.0
POLAR ACS23) Multi-center, prospective ACS 100 1 year MACE: 4.0 1.0 1.0 1.0
Gori et al.24) Single-center, prospective ACS 150 1 month MACE: 10.7 4.0 N/A 2.7
BVS registry Göttingen25) Single-center, prospective Mainly ACS 195 834 days DOCE: 15.4 6.7 4.6 2.6
Kajiya et al.26) Single-center, prospective STEMI 11 53 days MACE: 9.1 0 0 0
Prague 1927) Multi-center, prospective STEMI 40 6 months MACE: 5.0 N/A N/A N/A
Wiebe et al.28) Single-center, prospective STEMI 25 6 months MACE: 8.3 4.2 0 0
BVS STEMI first29) Single-center, prospective STEMI 49 30 days DOCE: 2.6 0 0 0
BVS-EXAMINATION30) Multi-center, retrospective STEMI 290 1 year DOCE: 4.1 2.1 1.7 2.4
RAI registry31) Multi-center, prospective STEMI 122 6 months POCE: 4.9 4.1 4.1 2.5
Kochman et al.32) Single-center, prospective STEMI 23 229 days N/A 4.3 4.3 4.3
Chakraborty et al.33) Single-center, prospective STEMI 35 11.5 months N/A 0 0 0
Diletti et al.34) Substudy of Absorb cohort B Small vessel 41 2 years MACE: 7.3 4.9 2.4 0
Ielasi et al.35) Multi-center, retrospective ISR 25 7 months MACE: 8.0 4.0 8.0 0
Moscarella et al.36) Multi-center, prospective ISR 83 7 months MACE: 12.0 N/A 7.7 2.4
RIBS-VI37) Multi-center, prospective ISR 141 1 year MACE: 12.8 2.8 11.3 0.7
ACS = acute coronary syndrome; AMC = Academic Medical Center; ASSURE = An Absorb post-marketing surveillance registry to monitor the everolimus-eluting 
bioresorbable vascular scaffold in patients with coronary artery disease; BRS (BVS) = bioresorbable vascular scaffold; DM = diabetes mellitus; DOCE = device-
oriented composite endpoint; GHOST-EU = Gauging coronary Healing with bioresorbable Scaffolding plaTforms in EUrope; ISAR-ABSORB MI = A Prospective, 
Randomized Trial of Bioresorbable Vascular Scaffold Versus Everolimus Eluting Stent in Patients Undergoing Coronary Stenting for Myocardial Infarction; ISR 
= in-stent restenosis; MACE = major cardiac adverse event; MI = myocardial infarction; MICAT = Mainz IntraCoronAry daTabase; N/A = not applicable; PCI 
= percutaneous coronary intervention; POCE = patient-oriented composite endpoint; POLAR ACS = POLishAbsorb Registry for ACS Patients; RAI = Registro 
Absorb Italiano; RIBS-VI = Restenosis Intra-stent: drug eluting Balloon vs. everolimus-eluting Stent-VI; SPIRIT = A Clinical Evaluation of the XIENCE V Everolimus 
Eluting Coronary Stent System; ST = stent thrombosis; STEMI = ST-segment elevation myocardial infarction; TLF = target lesion failure; TLR = target lesion 
revascularization; TVF = target vessel failure.
KOREAN EXPERIENCE
The Absorb BRS has been used since October 2015 in Korea. As of August 2017, a total of 2,833 
BRSs were implanted. Among those, only 9 scaffold thrombosis were reported in 9 patients. 
All patients presented with ACS (5 acute MI, 4 unstable angina). BRSs were implanted under 
the intracoronary imaging guidance in all cases. Postdilatation was performed in 8 patients. 
Scaffold thrombosis occurs in 2 cases within 24 hours and in 7 cases between 1 day and 30 days. 
No late scaffold thrombosis was reported. Possible mechanisms of scaffold thrombosis are 
early continuation of DAPT in 5 cases, underexpansion in 4 cases, and scaffold malapposition 
in 1 case. All patients were successfully treated without events (Table 3).
Interventional Cardiology Research In-cooperation Society Fractional Flow Reserve 
Bioresorbable Vascular Scaffold (IRIS BVS) registry is the ongoing prospective, multicenter 
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Table 3. BRS thrombosis from Korean population
Characteristic Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Sex/age M/54 M/45 M/67 M/87 F/75 F/68 M/58 M/73 M/74
Diagnosis UA NSTEMI NSTEMI STEMI UA UA NSTEMI STEMI ACS
Location m LAD p LAD m LAD m LAD p LAD p-m LAD m LAD m LAD m LAD
BRS (mm) 3.5×28 2.5×18 2.5×28 3.0×18 3.0×18 3.5×28 3.5×28 3.0×23 3.0×18
Image guidance IVUS OCT OCT OCT OCT IVUS/OCT IVUS/OCT None IVUS
Post-dilatation Done Done Done Not done 
(complete 
Scaffold 
apposition)
Done Done Done Done  
(3.5×12 mm)
Done  
(3.0×12 mm)
Days post-procedure 12 days 14 days 20 days 8 days 7 days 5 hours 13 days 7 hours 2 months
DAPT Aspirin, 
Clopidogrel
Aspirin, Ticagrelor Aspirin, 
Ticagrelor
Aspirin, 
Clopidogrel
Aspirin, 
Clopidogrel
Aspirin, 
Clopidogrel
Aspirin, 
Ticagrelor
Aspirin, 
Clopidogrel
Aspirin, 
clopidogrel
D/C for 3 days D/C for 2 days D/C for 3 days D/C for 5 hours D/C for 3 days
Possible mechanism DAPT D/C DAPT D/C DAPT D/C Under-
expansion
Under-
expansion
Jailed diagonal 
branch
DAPT D/C Scaffold 
malapposition
DAPT D/C
Underexpansion Underexpansion
Outcomes Survival Survival Survival Survival Survival Survival Survival Survival Survival
ACS = acute coronary syndrome; BRS = bioresorbable vascular scaffold; DAPT = dual antiplatelet therapy; D/C = discontinuation; IUVS = intravascular ultrasound; 
LAD = left anterior descending; m = mid; NSTEMI = non-ST-segment elevation myocardial infarction; OCT = optical coherent tomography; p = proximal; ST = stent 
thrombosis; STEMI = ST-segment elevation myocardial infarction; UA = unstable angina.
registry to enroll all patients who underwent the Absorb BRS implantation from 15 Korean 
heart centers. Preliminary data of early 352 patients was presented at Transcatheter 
Cardiovascular Therapeutics Angioplasty Summit (TCTAP) 2017. All procedures were 
performed under the intracoronary imaging guidance. Predilatation was performed in 94%; 
postdilation with non-compliant balloon in 99%. Mean scaffold diameter was 3.5±1.9 mm. 
Final non-compliant balloon pressure was 19.5±5.3 mm. Final balloon diameter was 3.6±0.3 
mm. Mean balloon to artery ratio was 1.22±0.30. Mean inflation time was 25±12 seconds. At 
1 year, no scaffold thrombosis occurred. Only 2 TLFs related with periprocedural MI occurred 
(Table 4). Compared with other studies, the IRIS BVS registry had the higher rate of imaging 
guidance, and pre- and postdilation. This could be a plausible reason of favorable BRS 
outcomes with very low rate of scaffold thrombosis in Korea, although preliminary.
INDICATIONS FOR BRS IMPLANTATION
Patient selection
As current BRSs resolve 2–3 years after implantation, improvement in outcome comparing 
with metallic DESs is expected in long-term over those periods. Therefore, ideal BRS 
candidate is a relatively young with a good life expectancy (>5 years). On the other hand, the 
use of BRS in patients with limited life expectancy with multiple comorbidities, and at high 
bleeding risk was not supported.38)
Lesion selection
BRS can be implanted in non-complex lesions including de novo lesions with diameter of 
2.25–4.0 mm on on-site quantitative coronary angiography (QCA), relative short lesions, and 
stable angina presentation. The culprit lesion of ST segment elevated MI, bifurcation lesion 
treating with 2 scaffolds, and aorto-ostial lesion, extreme tortuous vessel and small vessel 
(<2.25 mm) were less favorable lesions for BRS implantation. Table 5 summarized the BRS 
favorable patient and lesion characteristics.38)
BRS specific implantation techniques
Optimal sizing and BRS implantation technique is of paramount importance for achieving 
favorable long-term outcomes. Operators should understand that thick scaffold struts and 
their plastic nature results in a lower lumen gain and a smaller post-implanted minimal lumen 
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Table 4. IRIS BVS registry: 1 year outcome (n=352)
Variable No. of patients (%)
Device-oriented endpoint
TVF 2 (0.45)
Cardiac death 0 (0.0)
MI 2 (0.45)
Periprocedural MI 2 (0.45)
Spontaneous MI 0 (0.0)
Target-vessel revascularization 0 (0.0)
Scaffold thrombosis 0 (0.0)
Patient-oriented endpoint
Death from any cause 0 (0.0)
Cardiac death 0 (0.0)
Non-cardiac death 0 (0.0)
Stroke 0 (0.0)
IRIS BVS = Interventional Cardiology Research In-cooperation Society Fractional Flow Reserve Bioresorbable 
Vascular Scaffold; MI = myocardial infarction; TVF = target vessel failure.
diameter compared with conventional metallic DES. Importantly, report that early scaffold 
thrombosis occurs at a time when most patients received DAPT suggested that scaffold 
thrombosis would be related to procedure related factors.5) In addition, in randomized trials 
and registry studies, the optimal techniques for BRS implantation was underused. The systemic 
introduction of a BRS-specific protocol which has come to be known as preparation, sizing, and 
postdilatation (PSP) are associated with an up to 70% decrease in scaffold thrombosis to rates 
similar to those reported in metallic DESs (Figure 4).18) We suggest the “effective” PSP methods 
for BRS implantation (Table 6, Figure 5).38)39)
Step 1. lesion preparation with predilatation
The lesions should be prepared using adequate predilatation with semi or non-compliant 
balloon (1:1 vessel to balloon ratio). At the same time, operator should be cautious to avoid 
severe dissection over the BRS covered zone. Particularly for calcified lesions, aggressive 
lesion preparation is mandatory due to the relatively lack of sufficient radial force in BRS. 
Scoring/cutting balloon or rotational atherectomy can be used with lower threshold.40) If 
predilatation balloons cannot fully expand lesions, BRS implantation should be avoided.
Step 2. sizing and implantation
Intracoronary imaging including intravascular ultrasound or optical coherent tomography 
is a useful tool to assess pre-intervention lesion characteristics and optimize stent 
implantation.41) However, even in clinical trial setting, intracoronary imaging was 
significantly underused.7)42)43) In addition, angiography guidance with visual estimation may 
be inaccurate.44)
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Table 5. BRS favorable patient and lesion characteristics
• A relatively young with a good life expectancy (>5 years)
• De novo lesions
• Diameter 2.35–4.0 mm on QCA
• Maximum length 28 mm
• One BRS scaffold overlap
• Stable or silent ischemia
BRS = bioresorbable vascular scaffold; QCA = quantitative coronary angiography.
Table 6. Effective PSP
Prepare lesion
• Use a non-compliant balloon (1:1 balloon to vessel ratio)
• Encourage scoring/cutting balloon or rotational atherectomy in calcified lesions
• Avoid BRS implantation in the lesion not achieving full balloon expansion
Sizing
• Use intracoronary imaging to select adequate device size
• Otherwise, use on-line QCA with automatic calibration to select device size
•  Select device size relying on the proximal Dmax on on-line QCA  
(example) 
  
Postdilatation
• Use a non-compliant balloon with 0.5 mm bigger size than scaffold with high inflation pressure (16–25 atm)
• Target balloon to artery ratio of >1.2 (or balloon to device ratio of >1.15)
• Maintain target pressure for at least 30 seconds
BRS = bioresorbable vascular scaffold; Dmax = maximal lumen diameter; PSP = preparation, sizing, and 
postdilatation; QCA = quantitative coronary angiography.
QCA proximal Dmax (mm) BRS size (mm) Final balloon diameter (mm)
2.5 2.5 3.1–3.2
3.0 3.0 3.6–3.7
3.5 3.5 4.1–4.2
Instead, online QCA with automatic calibration offers reliable assessment of vessel sizing 
without additional cost.45)46) We suggest that BRS sizing relies on proximal and distal maximal 
lumen diameter (Dmax) at the level of intended BRS implantation zone after nitroglycerin 
administration.47) Except in case of extreme vessel tapering, the scaffold selection should match 
the proximal Dmax in proximal device landing zone. Considering Dmax from online QCA is 
about 0.5 mm smaller than vessel diameter from intracoronary imaging,48) this sizing method 
with additional bigger non-compliant balloon inflation can well-negotiate the risk between 
underexpansion of proximal edge and dissection of distal edge. In addition, this strategy can limit 
excessive scaffold/artery ratio, and may decrease thrombogenicity, and neointimal thickness.49)50)
BRS should cover normal looking segment at either edge of lesion. Scaffold deployment 
should be performed slowly with long-duration. In general, high-pressure inflation 
with delivery balloon was not recommended. When implanting multiple BRS, minimal 
overlapping techniques to minimize scaffold thickness are suggested such as “marker-to 
marker” (up to 1 mm of overlap) or “scaffold-to-scaffold” (no overlap) technique.8)
Step 3. postdilatation with a non-compliant balloon
Postdilitation is also very important during BRS implantation. In previous registry, all acute 
or subacute BRS thrombosis occurred in severe underexpanded scaffold.51) Postdilatation 
uses a non-compliant balloon with 0.5 mm bigger size than scaffold device with high 
inflation pressure (16–25 atm). Recent data showed that higher balloon to artery ratio (>1.2, 
or balloon to device ratio >1.15) was associated with expansive vessel wall remodeling.52) 
Target pressure should be maintained for at least 30 seconds, because a significant larger 
lumen diameter is obtained with a longer inflation time.53)
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Figure 5. A case of “Effective” PSP. Fifty-seven years old man admitted due to effort related chest pain. Coronary angiography showed tight stenosis of LAD artery 
(A). On-line QCA showed that proximal Dmax was 3.1 mm and distal Dmax was 2.6 mm (E-G). Predilatation was performed using 3.5×1.5 mm non-compliant 
balloon (B). Absorb BRS 3.0×23 mm was implanted (C). Postdilatation was done by 3.5×15 mm non-compliant balloon up to 18 atm (final balloon diameter: 3.6 
mm). Final optimal coherent tomography showed well expanded and apposed scaffold without acute complications. 
BRS = bioresorbable vascular scaffold; Dmax = maximal lumen diameter; LAD = left anterior descending; MLD = mean lung dose; NC = non-compliant; PSP = 
preparation, sizing, and postdilatation; QCA = quantitative coronary angiography; RVD = reference vessel diameter.
TREATMENT FOR BRS FAILURE (SCAFFOLD 
THROMBOSIS AND IN-SCAFFOLD RESTENOSIS)
Understanding the fundamental pathophysiological mechanism underlying BRS failure 
is of key importance to guide proper subsequent treatment.54) Therefore, intracoronary 
imaging study is highly recommended in cases of BRS failure.55) Multiple treatment strategy 
for treating BRS failure was proposed including DES, plane balloon angioplasty, drug-
coated balloon, or BRS.55)56) Mechanical causes can be treated first with balloon angioplasty 
with non-compliant balloon. In-scaffold restenosis due to neointimal hyperplasia can be 
treated by a drug-coated balloon. If mechanical factors cannot be corrected by balloon 
angioplasty, DES implantation can be considered. In addition, if BRS failure occurs 6 months 
after implantation, DES or BRS implantation can be considered because after 6 months 
disintegration of the scaffold begin and additional radial strength is necessary.55)
HYBRID PERCUTANEOUS CORONARY INTERVENTION
Due to the clinical and mechanical limitations of current generation BRS, complex 
coronary lesions are frequent unsuitable for pure BRS implantation. To minimize the 
length of permanent metallic caging, and achieving optimal BRS result, hybrid approach 
in combination of BRS, DES, and drug-coated balloon was proposed.57) For the BRS less 
favorable lesion including large vessel, aorto-ostial lesion, side-branch of bifurcation, large 
size discrepancy, and small vessel, conventional DES was implanted. Drug-coated balloon 
can be used in small diffuse coronary artery disease.58) BRS was implanted only in BRS 
favorable lesions overlapping with DES. Aggressive post-dilatation should be performed at 
the overlapping site to minimize the risk of late malapposition of metallic DES after complete 
resorption of BRS.57)
ANTIPLATELET THERAPY AFTER BRS IMPLANTATION
For metallic DES, at least 6-month DAPT after PCI for stable ischemic heart disease, and 
12-month for ACSs are recommended in American and European guidelines.59)60) However, 
optimal duration of DAPT for BRS remains to be evaluated. Randomized trials stated the use 
of DAPT for at least 1 year per protocol.6)7)42)43) Regarding several reports on early as well as 
late scaffold thrombosis,61) some physicians suggest the longer DAPT regimen (>12 months), 
and/or more potent agents (e.g., ticagrelor or prasugrel)62)63) or triple antiplatelet therapy, 
particularly in the early period after BRS implantation. In this context, patients who cannot 
tolerate a long-term DAPT or are at high risk of bleeding may not be ideal candidate for BRS 
implantation.
LESSONS FROM FIRST GENERATION ABSORB BRS
At 14th September 2017, Abbott Vascular announced a halt to sales of the Absorb BRS. The 
experience of the first generation BRS provides the valuable insight for the next generation 
(Figure 6). First, the new BRS needs to be mechanically stronger, have thinner struts, and 
available in a broad range of length and diameter. In addition, complete biodegradation 
occurs without significant inflammatory reaction within 1–2 years. Second, treating 
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physicians should realize that BRS profiles may differ significantly from conventional 
metallic DESs and should adopt specific BRS implantation technique for favorable outcomes. 
Third, new BRS should be extensively tested in a stepwise fashion from relatively simple 
lesion to more complex lesion.
CONCLUSION
Although promising early reports, recent studies have raised concerns about the safety and 
efficacy of BRS compared with contemporary standard metallic DESs. However, we have 
experienced in the interventional technology field that the drawbacks of old device have 
greatly motivated technological innovation to solve previous problems. With rapid evolving 
technology of BRS under a number of current ongoing clinical tests, newer BRS overcoming 
current issues are expected in a near future.
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